Tucson, AZ (PRWEB) July 11, 2015
Evan Unger, President and CEO of NuvOx, announced today that Mike Sember, will join the Board of Directors of NuvOx Pharma. Mike has more than 40 years of comprehensive experience working with public and private pharmaceutical, biotech and medical device companies in the U.S. and Europe. He has experience in the areas of R&D, business development, strategy and corporate finance, including involvement with over 100 licensing transactions and corporate acquisitions. Previously, Mike served in senior positions with Marion Laboratories (Marion Merrell Dow) and Elan Corporation. Mike has been CEO or COO of five public and private corporations. He has served on the boards of 14 public and private companies and also on the advisory boards of several venture capital firms. Mike Sember said, “I am pleased to join the NuvOx Board. NuvOx is a clinical stage biopharmaceutical company with a revolutionary nanotechnology platform that has potential to improve outcomes in life-threatening diseases where hypoxia (low oxygen) is paramount. My background in the pharmaceutical industry will help NuvOx as the company approaches and succeeds in commercialization of its technologies."